4/A: Ionis Pharmaceuticals CEO Brett Monia Amends Form 4 Filing to Correctly Report Stock Sale

Brett Monia, CEO of Ionis Pharmaceuticals, amended a previous Form 4 filing to accurately reflect the number of shares sold on February 2, 2024.

Summary

• Brett Monia, the CEO of Ionis Pharmaceuticals, filed an amendment to a Form 4 document.
• The amendment corrects the number of restricted stock units sold on February 2, 2024.
• The corrected filing shows that 23,907 shares of common stock were sold at a weighted average price of $49.3725.
• The sales occurred in multiple transactions with prices ranging from $49.22 to $49.51.
• Following the reported transaction, Monia beneficially owns 173,732 shares.
• The reporting person will provide full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4, upon request.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing amendment, indicating a neutral sentiment.

Industry Context

Form 4 filings are standard practice for reporting transactions by company insiders, such as directors and officers, in their company's stock. Amendments are sometimes necessary to correct errors or omissions in the original filings.

Stakeholder Impact

• Shareholders may be interested in insider transactions as they can provide insights into management's perspective on the company's stock.

Key Dates